Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Background Reaching the therapeutic target of remission or low-disease activity has
improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target …

Importance Proactive therapeutic drug monitoring (TDM), consisting of individualized
treatment based on scheduled assessments of serum drug levels, has been proposed as an …

Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-αあるふぁ inhibitor therapy in patients with active …

Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …

Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2
that may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted …

Importance Proactive therapeutic drug monitoring (TDM), defined as individualized drug
dosing based on scheduled monitoring of serum drug levels, has been proposed as an …

Summary Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor,
showed efficacy in combination with stable background conventional synthetic disease …

Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …